Tindara Franchina

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

Alessandro Russo, Marco Russano, Tindara Franchina et al. · Advances in Therapy · 2020 · 168 citations

Medicine, Immunology, Oncology +17

Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer

Tindara Franchina, Valeria Amodeo, Giuseppe Bronte et al. · Journal of Cellular Physiology · 2013 · 117 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

Alessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi et al. · Journal of Cellular Physiology · 2018 · 100 citations · Full text

Medicine, Immunology, Oncology +17

Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients

Giuseppina Rosaria Rita Ricciardi, Bárbara Adamo, Antonio Ieni et al. · PLoS ONE · 2015 · 71 citations · Full text

Medicine, Cancer Biology, Oncology +16

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review

Giuseppina Rosaria Rita Ricciardi, Alessandro Russo, Tindara Franchina et al. · BMC Cancer · 2018 · 49 citations · Full text

Medicine, Oncology, Radiation Oncology +17